ADVA
13.7.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced the Cyprus Telecommunications Authority (Cyta) is leveraging its timing technology in a national synchronization network, addressing legacy timing applications and ensuring a smooth migration to precise packet timing for 5G critical services in the future. The solution enables Cyta to meet the stringent timing requirements of next-generation services while supporting all existing mobile technologies. ADVA’s Oscilloquartz PTP grandmaster clock and GNSS receiver technology not only enhances synchronization precision but also provides new levels of resilience and reliability. The project was facilitated by ADVA’s partners, the ICT solutions providers GCC Computers Ltd and ADAPTIT S.A., which will also provide ongoing technical support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005088/en/
“Cyta now has a synchronization network able to address the accuracy, efficiency and stability demands of 5G. With support for NTP, PTP and SyncE, our technology ensures that the new infrastructure meets the needs of Cyta’s legacy applications, ensuring a smooth migration to the precise packet timing that is critical for 5G services,” said Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Together with GCC’s and ADAPTIT S.A.’s teams, we’ve engineered a solution that fits Cyta’s exact requirements. It provides the sub-microsecond accuracy necessary for advanced mobile applications together with hardware redundancy for unbeatable resilience. What’s more, our Ensemble Controller network management technology makes it simple to operate.”
Prior to the deployment, Cyta’s timing network was based purely on frequency synchronization. It now distributes stable and accurate phase and time-of-day information, supporting the enhanced spectrum utilization needed for 5G. The solution features the OSA 5420 Series of grandmaster clocks, optimized for mobile backhaul and fronthaul in the radio access network. In the core, the OSA 5440 provides highest accuracy and availability with its dual multi-band, multi-constellation GNSS receiver and full hardware redundancy. The technology is remotely controlled by ADVA’s Ensemble Sync Director. This provides a powerful management platform, giving Cyta full visibility of its synchronization infrastructure and assuring perfect end-to-end timing.
“We’ve worked closely with Cyta to create a synchronization solution that fits its precise needs. Able to support both legacy and next-generation packet networking, Cyta’s new timing network is space- and power-efficient, assured by in-service PTP and GNSS monitoring and protected by hardware redundancy. Our engineers have also provided support at every stage of the process and made certain that the installation was carried out without any disruption to services,” commented Vasileios Karavasilis, commercial director, ADAPTIT S.A. “As a key distributor of ADVA’s Oscilloquartz solutions, we know all about the value of precise and reliable timing in mission-critical networks. Cyta is now prepared for mass 5G rollout with a synchronization architecture able to meet key challenges both now and in the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
About GCC Computers Ltd.
GCC Computers has a distinguished market presence in Cyprus as an ICT System Integrator and has built a strong reputation as the employer of the best technology professionals. For more than 30 years, GCC has been acknowledged with considerable success serving Public/Government, Telecommunications & Utilities, Banking/Finance and SME (Small-Medium-Enterprise) sectors with innovative solutions. GCC’s expertise and extensive partnerships help clients harness the technology power to thrive on change and guide their digital transformation journeys. For more information, please visit us at www.gcc.com.cy .
About ADAPTIT S.A.
ADAPTIT S.A. is a highly specialized System Integrator that combines latest technology trends to offer its clients innovative tailor-made solutions, according to their needs, and finally delivers high-quality TURNKEY PROJECTS, ensuring the highest possible performance of their investment. With a wide-range portfolio of networking solutions ADAPTIT provides networking expertise to Service Providers, Government Agencies and Enterprises. ADAPTIT S.A. has presence in most European countries, having delivered similar major projects to several Service Providers in Spain, Sweden, Finland, Portugal, Poland, Romania, Malta, Bulgaria, and Albania. For more information, please visit us at www.adaptit.gr .
About Cyta
Cyta is the leading provider of integrated electronic communications in Cyprus. Making the most of its technologically advanced networks, it offers a wide range of services and solutions to meet the ever-increasing demands of its residential and business customers for voice, data and content applications. With a pivotal role in the digital transformation of Cyprus, Cyta is deploying an island-wide, fiber-optic network, while it progressively upgrades its mobile network technology. It advances and maintains subsea and satellite networks for international connections of strategic importance that have established Cyprus as a regional telecommunications and connectivity hub in the Eastern Mediterranean. www.cyta.com.cy
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005088/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom